Sangamo BioSciences, Inc. (NASDAQ: SGMO) has ticked higher on its report demonstrating that new clinical data is demonstrating persistent positive effects of ZFN Therapeutic as a functional cure of HIV/AIDS. While the term ‘Cure” is one that is up for debate, two presentations were presented this week:
“These data differentiate SB-728-T from other novel therapies as a feasible approach to controlling HIV/AIDS,” said Ronald Mitsuyasu, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA and a principal investigator in Sangamo’s SB-728-T studies. “The results suggest that SB-728-T has a positive effect on immune health of HIV-infected patients and this effect is persistent for over a year in some subjects. Most importantly, SB-728-T treatment provides HIV-resistant T-cells that are capable of mounting an immune response to an inflammatory event in lymphoid tissues and has yielded encouraging effects on HIV viral load when antiretroviral drugs are withdrawn during a treatment interruption.”
The company has a Phase II trial underway. Full details are here of the presentations this week.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks